On April 16, 2015, Joshua R. Disbrow resigned as Chief Operating Officer of Ampio Pharmaceuticals, Inc. in connection with the Merger (as defined below) to assume the role of Chief Executive Officer of Rosewind. On April 16, 2015, Luoxis Diagnostics, Inc. and Vyrix, each previously a subsidiary of Ampio, entered into an agreement and plan of merger by and among Rosewind, Luoxis, Vyrix, two major stockholders of Rosewind and two subsidiaries of Rosewind created solely for the purposes of the merger.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.22 USD | -8.94% | -18.52% | -89.27% |
15/04 | Ampio Pharmaceuticals, Inc.(NYSEAM:AMPE) dropped from S&P TMI Index | CI |
27/03 | Ampio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-89.27% | 3L | |
+9.58% | 11TCr | |
+12.41% | 11TCr | |
-2.59% | 2.2TCr | |
-12.38% | 2.19TCr | |
-5.29% | 1.92TCr | |
-3.35% | 1.81TCr | |
-38.57% | 1.77TCr | |
+7.51% | 1.43TCr | |
+35.67% | 1.24TCr |
- Stock Market
- Equities
- AMPE Stock
- News Ampio Pharmaceuticals, Inc.
- Ampio Pharmaceuticals, Inc. Announces Resignation of Joshua R. Disbrow as Chief Operating Officer